Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration : a pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG) by Witte, T.J.M. de et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/20437
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Leukemia (1995) 9 ,1805-1811 
© 1995 Stockton Press All rights reserved 0887-6924/95 $12.00
Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary 
acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A 
pilot study by the Leukemia Cooperative Group of the European Organisation for 
Research and Treatment in Cancer (EORTC-LCG)
T de Witte1, S Suciu2, M Peetermans3, P Fenaux4, P Strijckmans5, M Hayat6, B Jaksic7, D Selleslag0, R Zittoun9,
M Dardenne2, C Solbu2, H Zwierzina10 and P Muus1
'Division of Hematology, University Hospital St Radboud, Nijmegen, The Netherlands; 2EORTC Data Center, Brussels, Belgium;
*Universiteits Ziekenhuis Antwerpen, Edegem, Belgium; 4Centre Hopitalier et Universitaire de Lille, Lille, France; 5Institut Jules Bordet, 
Brussels, Belgium;6Institut Gustave Roussy, Villejuif, France;7University Hospital Merkur, Zagreb, Croatia; aSt Jan's Hospital, Brugge, 
Belgium;9Hôpital Dieu, Paris, France; and 10Medische Klinik Innsbruck, Innsbruck, Austria
We conducted a prospective, multicenter pilot study of 
remission induction therapy in patients with poor prognosis 
MDS and AML evolving from a preceding phase of MDS. Fifty 
evaiuable patients from 15 institutions were treated with one or 
two rémission-induction courses consisting of i.v. idarubicin
12 mg/m2/day on days 1, 2, and 3 combined with a continuous 
i.v. infusion of cytarabine of 200 mg/m2/day on days 1 to 7. Of 
the 27 compiete remitters (54%), 23 received a consolidation 
course which was identical to the rémission-induction course 
except for the idarubicin 12 mg/m2 which was given on day 1 
only. Fifteen patients received maintenance therapy consisting 
of six courses of cytarabine 10 mg/m2, s.c. twice daily, for 14 
days. Two complete remitters were allografted and five patients 
received an ABMT. The median survival of all 50 treated pati­
ents was 14 months. The median duration of disease-free sur­
vival was 11 months with two patients in CR more than 2 years 
after entering CR. Twenty-four of the 27 remitters have 
relapsed. Four patients died during rémission-induction ther­
apy, but no patient died as a result of persisting hypoplasia. 
No fatal complications occurred during the consolidation and 
maintenance courses. Age and stage of disease had no sig­
nificant impact on CR rate nor on remission duration. The CR 
rate was significantly (P = 0.03) higher in patients with only 
normal metaphases compared to patients with cytogenetic 
abnormalities. The DFS at 2 years was 33 vs 8%, respectively, 
for patients without or with cytogenetic abnormalities 
(P = 0.02). This study shows that patients below the age of 60 
years with poor risk features are candidates for treatment with 
combination chemotherapy. A complete remission rate of more 
than 50% may be expected. Maintaining remission after 
remission-induction chemotherapy is a difficult issue. Patients 
not eligible for allogeneic BMT may be treated with intensive 
post-remission chemotherapy or autologous BMT.
Keywords: myelodysplastic syndrome; secondary acute myeloid 
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Introduction
Myelodysplastic syndromes (MDS) form a group of disorders 
of the hematopoietic stem cell with a variety of clinical and 
laboratory features.1"4 MDS have been classified by the 
French-American-British (FAB) Group into five subcategories: 
refractory anemia (RA), refractory anemia with ringsidero- 
blasts (RARS), refractory anemia with excess of blasts (RAEB), 
refractory anemia with excess of blasts in transformation 
(RAEBt), and chronic myelomonocytic leukemia (CMML).5 
Clonal cytogenetic abnormalities have been reported in 23-
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78% of cases with MDS,6,7 In contrast to AML, MDS is often 
associated with chromosome deletions as a primary kary- 
otypic abnormality. Translocations such as t(8;21 ) and t(15;17) 
which are characteristic of certain types of AML are rare.8
The clinical course of the myelodysplastic syndromes varies 
from an indolent form to a rapidly fatal disease. RA or RARS 
are characterized by a low risk of transformation to acute 
myeloid leukemia and a median survival usually exceeding 
30 months.13 Median survival of patients with RAEB or RAEBt 
is less than 1 2 months despite any treatment given.10 Patients 
with a normal karyotype have a better prognosis than those 
with single abnormalities/3'7 Patients with complex cyto­
genetic abnormalities have the worst prognosis/1'7'11
The generally accepted policy of treatment for most patients 
with MDS is supportive therapy.12 Androgens/3 low-dose 
cytarabine,14 vitamin A and vitamin D analogs15'16 have been 
assessed in pilot studies, but failed to induce a substantial per­
centage of complete remission or better survival than the con­
trol group treated with supportive care only.17*19 Adminis­
tration of recombinant granulocyte(-macrophage) colony- 
stimulating factor, erythropoietin and interleukin-3, alone 
or in combination, induced clinically relevant responses in 
some patient categories, but overall survival was not 
influenced.20-25
More intensive treatment approaches are being explored in 
younger patients in view of the relatively short median sur­
vival of less than 12 months in most categories of patients. 
Some young patients may achieve prolonged, disease-free sur­
vival after treatment with combination chemotherapy.26-20 
Prospective, multicenter studies have not been performed in 
patients with MDS.
For these reasons we initiated a prospective, multicenter 
pilot study of remission-induction therapy, similar to the treat­
ment of de novo AML in patients younger than 60 years of 
age, for patients with poor prognosis MDS and AML evolving 
from a phase of MDS. In view of promising preliminary studies 
it was decided to replace the conventional anthracycline, dau- 
norubicin, by the potentially more active anthracycline 4- 
demethoxyclaunorubicin (idarubicin).29'30 The major aim of 
this study was to assess the value and toxicity of remission- 
induction combination chemotherapy in poor prognosis and 
transformed MDS in terms of partial and complete response 
rate, duration of hypoplasia and death rate during hypoplasia. 
The second aim of the study was to assess the feasibility and 
toxicity of a less intensive consolidation course followed by 
maintenance therapy with six courses of low-dose cytarabine 
in those patients not eligible for allogeneic BMT. The final aim 
was to study overall survival and disease-free survival (DFS).
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Patients and methods
Patient selection criteria
The following patients were eligible for study: (1 ) patients with 
refractory anemia (RA), RA with ringsideroblasts (RAS) or 
RAEB with ^10% blasts in the marrow and multiple chromo­
somal abnormalities; (2) RAEB with >10% blasts in the bone 
marrow; (3) all patients with RAEB in transformation (RAEBt);
(4) chronic myeiomonocytic leukemia (CMML) with a neu­
trophil count of > 1 6 X 1 09/l or a monocyte count of 
>2.6 X 1071 in the blood or 5%  blasts in the bone marrow; 
and (5) all patients with secondary AML supervening on overt 
MDS of more than 3 months duration.
Exclusion criteria were the following: (l)age less than 15 
years or more than 60 years; (2) previous intensive chemo­
therapy, and/or radiotherapy for MDS or AML; (3) treatment 
with biological response modifiers and/or low-dose cytarabine 
within 2 months prior to entry; (4) no informed consent;
(5) performance status W H O  scale 3 or 4; and (6) life expect­
ancy of >3 months.
Design o f the protocol
The remission-induction course consisted of idarubicin 
12 mg/m2/ciay as a 5 min i.v. injection on days 1, 2, and 3 
combined with a continuous i.v. infusion of cytarabine of 
200 mg/m2/day on days 1 to 7 (total 7 days). In case of partial 
response one additional identical remission-induction course 
was to be given. The remaining patients with a poorer 
response were taken off study. Patients entering a CR after one 
or two courses of remission therapy received consecutively 
one consolidation course starting 4 weeks after the beginning 
of the (last) remission-induction course. The consolidation 
course was identical to the remission-induction course except 
for the idarubicin which was given on day 1 only in the same 
dosage of 12 mg/m2.
HLA-typing of patients, parents and siblings was initiated at 
the onset of induction therapy in all patients younger than 40 
years (or younger than 50-55 years according to the policy of 
the center). In case of a HLA-A, -B, -Dr identical, MLC nonre­
active sibling, a one locus class-l mismatched sibling or a 
phenotypically identical parent, the patient was proposed for 
allografting. The allo-BMT was planned as soon as possible 
after recovery from the consolidation course. Patients not eli­
gible for allo-BMT were scheduled to receive maintenance 
therapy consisting of six courses of cytarabine 10 mg/m2, s.c. 
twice daily, for 14 days with 4-weel< intervals between the 
courses.
Required clinical investigations
Pretreatment bone marrow and blood smears were centrally 
assessed by the MDS section of the pathology review commit­
tee of the EORTC-LCC (coordinator: Dr H Zwierzina), The 
classification of MDS and AML was performed according to 
the criteria of the FAB working group. One smear of bone 
marrow and blood was also reviewed centrally at the time of 
CR or first relapse. Apart from the other standard investigations 
it was strongly recommended to perform cytogenetic analysis 
with banding techniques prior to the start of chemotherapy.
Definitions
AML evolved from myelodysplasia was defined as secondary 
AML (sAML). AML after chemotherapy or radiotherapy was 
defined as therapy-related AML (t-AML).
Complete remission (CR) was defined as absence of clinical 
manifestations of leukemia and less than 5% blasts in a nor- 
mocellular marrow with normal morphology. The peripheral 
blood neutrophil count should be ^1.5 x 1071 and platelets 
more than 100 X 107L Normalization of cytogenetic abnor­
malities was not included in the definition of CR.
Partial remission was defined as 50% or more reduction of 
blasts in a normocellular marrow.
The duration of survival was calculated from the date of 
start of treatment until death. For patients who achieved CR 
after induction the DFS was calculated from the date of first 
CR until the data of first relapse or the date of death in first 
CR. The duration of survival of remitters corresponds to the 
time for first CR to the date of death or date of last follow-up.
Statistical methods
All patients were prospectively registered at the EORTC Data 
Center in Brussels. The relationship between the disease stage 
of the patient (MDS vs sAML) or response to induction (CR vs 
no CR) and different initial features was statistically tested 
using the x2 test.31 In case of ordered variables (cytogenetics), 
the x2 test for linear trend was used.31
Actuarial curves were calculated according to the Kaplan- 
Meier technique.32 The differences between curves were stat­
istically tested using the two-tailed log-rank test.33 For ordered 
variables the log-rank test for linear trend was used.33
Results
Clinical data
Fifty-one patients from 15 institutions were registered between 
September 1989 and March 1993. Sufficient data for evalu­
ation was available for 50 patients. The youngest patient was 
17 years old and the oldest patient was 60 years old. The 
median age was 46 years. Clinical data are presented in Table
1. Thirty-four patients had a form of MDS when chemotherapy
Table 1 Clinical data of 50 evaluable patients with MDS or sAML 
treated with 3/7 ida rubici n/cytarabin
MDS sAML P value
All patients 34 16
FAB subtypes
RAEB 9
RAEBt 21
CMMoL 4
Therapy-related MDS/sAML 3 5 0.11
Age
<40 years 10
40-49 years 12 6
50-60 years 12 10 0.014
Cytogenetic studies
Not performed/no metaphases 3 2
Only normal metaphases 5 5
Normal/abnormal metaphases 14 5
Only abnormal metaphases 12 4 NS
Simple abnormalities 8 1
Multiple abnormalities 18 8 NS
NS, not significant
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was initiated. Nine patients had RAEB, four patients CMML, 
and 21 patients were classified as RAEBt. Sixteen patients had 
progressed to AML prior to starting chemotherapy.
Treatment results
Twenty-six patients (52%) entered CR after one remission- 
induction course. Six patients received a second remission- 
induction course. One additional patient entered CR after 
administration of the second remission-induction course. 
Nine patients with cytogenetic abnormalities prior to 
rémission-induction therapy were re-evaluated cytogenet­
ically after having entered CR. A median number of 20 meta­
phases (range 10-73) were analyzed. Eight patients showed 
normal metaphases while one patient had persistent abnormal 
metaphases. Two additional patients showed normal meta­
phases during remission.
Four patients died during the remission-induction courses. 
Two died from toxic complications and two from infectious 
complications. None died from persistent or prolonged hypo­
plasia. Five patients achieved partial remission. Fourteen pati­
ents had either progression of the disease despite therapy2 or 
the disease status remained unchanged.12 None of the patients 
remained hypoplastic after the remission-induction courses.
Intensive salvage chemotherapy was administered to four 
patients outside the protocol. One of these four patients 
achieved a CR, but the disease status of the other three pati­
ents remained unchanged. One of these patients received an 
allogeneic BMT from a mismatched sibling and died from 
treatment-related complications. Three non-remitters were 
treated with allogeneic BMT with marrow from an histocom- 
patible sibling donor. Two patients died from relapse after 
allo-BMT and one patient died from veno-occlusive disease.
Twenty-seven patients were scheduled to receive the con­
solidation course. Four patients did not receive the consoli­
dation course in first CR due to poor clinical performance (two 
patients) or early relapse (two patients). All 23 patients who 
received the consolidation course maintained CR. Twenty- 
three patients were eligible for treatment with six courses of 
low-dose Ara-C. Two had a compatible donor and were 
scheduled for allo-BMT. An autologous bone marrow trans­
plantation (ABMT) was planned for a further six patients 
(performed in five patients). The remaining 15 patients 
received either all six courses (12 patients), five courses (one 
patient), or four courses (two patients). Three of these 15 pati­
ents are alive and well in first CR at the time of this analysis. 
One oí these three patients was consolidated with ABMT 666 
days after having achieved CR. The follow-up of these three 
patients is: 14, 35, and 45 months, respectively.
Nine patients were still alive at the time of the last analysis 
(June 20, 1994). Three patients were in continuing first 
remission. One patient has never achieved CR, but has had 
stable disease for 16 months since last treatment. Three pati­
ents relapsed but entered a second CR following intensive 
chemotherapy. All three patients were in second CR at the 
time of reporting. The median duration of second CR was 8 
months. One patient was alive without any further treatment 
after relapse. The ninth patient received a second allo-BMT 
after a first remission of 8 months and is in continuing 
second CR.
Bone marrow transplantation
Family typing was performed in 16 of 31 patients younger 
than 50 years. Only ten patients were younger than 40 years. 
The policy to perform allogeneic BMT in patients between the 
age of 40 and 50 years varied from center to center. Five pati­
ents had an identical sibling. Two of these patients achieved 
CR. One patient was transplanted in first CR, He relapsed 5 
months after BMT, but was retransplanted without a further 
attempt to induce remission prior to the BMT. He is alive and 
well in second CR 41 months after the second BMT. The other 
patient was transplanted in first relapse but died from relapse 
after BMT. The other three patients with a donor did not achi­
eve CR and were transplanted in partial remission. Two pati­
ents relapsed and the third died from treatment-related causes.
Five patients received an ABMT. Only the patient who had 
been transplanted after a CR duration of 666 days remained 
in CR. The other four patients have relapsed.
Overall results
The median duration of survival of all 50 treated patients was 
15 months (Figure 1 a). Twelve patients were alive 2 years after 
registration. The median duration of survival of the 27 com-
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Figure 1 (a) Actuarial survival of all 50 evaluable patients. 
N*. number oí patients; O: number of observed events, (b) Actuarial 
survival (solid line) or disease-free survival (dashed line) of 27 patients 
who reached CR after one or two remission-induction courses
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píete remitters was 21 months. The median disease-free sur­
vival was 11 months with two patients in CR more than 2 
years after entering CR (Figure 1b). Twenty-two of the 27 
remitters have relapsed and two patients have died in CR.
Toxicity o f chemotherapy
The toxicity was graded according to the standard W H O  cri­
teria. The major observed toxicity was infection during 
remission course and the consolidation course (Table 2). Four 
patients died during remission-induction therapy. Two pati­
ents died during the first week of therapy due to multi-organ 
failure and cardiac toxicity, respectively. One patient died on 
day 28 after initiation of therapy, mainly due to infectious 
complications, and the fourth patient died after the second 
remission-induction course was administered (58 days after 
registration) from infectious complications. No fatal compli­
cations occurred during the consolidation and maintenance 
courses.
Hospitalization duration
The median number of days spent in hospital during and fol­
lowing the first remission-induction course was 30 days with 
a range between 24 and 80 days. The three patients who died 
during this course were excluded. The median duration of 
hospitalization of the 26 patients who entered CR after one 
remission-induction course was 31 days with a range of 24-
44 days. The median time interval between start of remission- 
induction therapy to start of consolidation therapy was 40 
days. All 23 patients who entered CR after one course of 
remission-induction therapy and who received consolidation 
therapy started the consolidation course within 8 weeks after 
start of remission-induction therapy.
Prognostic variables
Several variables have been analyzed in order to assess their 
prognostic value. Leukocyte count, platelet count, marrow 
cellularity, the presence of Auer rods (present in five patients 
only) and the duration from diagnosis of MDS to start of 
chemotherapy had no major impact on treatment outcome 
(data not shown).
MDS vs sAML
Thirty-four patients with MDS were treated with one or two 
remission-induction courses and 17 patients (50%) achieved
CR. Five out of nine patients (55%) with the morphological 
picture of RAEB, 10 of the 21 patients (48%) with RAEBt and 
two of the four patients with CMML (50%) entered CR. Ten 
of 16 patients (63%) with AML at initiation of chemotherapy 
achieved CR. The CR rates between the different subgroups 
were not significantly different. Median survival of the 34 pati­
ents with MDS was 12 months compared to 21 months for 
the 16 patients with sAML (P = 0.18). The DFS was signifi­
cantly longer (P = 0.03) for those patients who were treated 
after progression to AML. The median DFS was 7 months for 
the patients with MDS and 17 months for the patients with 
AML.
Age
Significantly (P -  0.014) more younger patients had the mor­
phological picture of MDS at the start of treatment (Table 1), 
Sixteen of the 31 patients (52%) younger than 50 years 
entered CR and 11 of the 19 patients (58%) older than 50 
years. Survival and DFS were similar in both age groups (data 
not shown).
Therapy-related MDS/sAML
Eight patients had been treated with cytotoxic agents for other 
malignancies or auto-immune disorders. Five of these patients 
had progressed to AML, Two of the eight patients with ther- 
apy-related MDS/AML entered CR (25%) and 25 of the 42 
primary cases (60%). These differences did not reach signifi­
cance (P = 0.15), mainly due to the low numbers. The overall 
survival at 3 years of the 42 primary patients was 29 vs 12% 
for eight patients with therapy-related MDS/AML (P = 0.28).
Cytogenetics
No cytogenetic data were available on five patients. In 10 pat­
ients only normal metaphases were found. Thirty-five patients 
had cytogenetic abnormalities (Table 1). Only one of these 
patients had a chromosomal abnormality associated with de 
novo AML. In this patient with a RAEBt a t(8;21) was observed 
in all 25 metaphases. This patient entered CR, but relapsed 
after 17 months. Cross tabulation of the cytogenetic data with 
other pretreatment variables did not disclose any significant 
association. However, six of the eight patients with post-cyto­
toxic MDS/AML showed cytogenetic abnormalities (P=  0.3).
The CR rates of groups stratified according to presence or 
absence of chromosomal abnormalities is shown in Table 3. 
The CR rate was significantly (P = 0.03) higher in patients 
with only normal metaphases compared to patients with cyto-
Table 2 Toxicity of chemotherapy'1
Remission-induction Consolidation-course Maintenance courses 
first course only
Number of evaluable patients 50 24 15
Infection 36 11 2
Hemorrhage 9 2 2
Diarrhoea 9 0 1
Cardio-vascular 1 0  0
aOnly toxicities of >grade 1 according to WHO criteria
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Figure 2 (a) Actuarial survival of 10 patients with normal cyto­
genetic metaphases (NN) prior to treatment (solid line) and 35 patients 
with abnormal metaphases (AN-AA) prior to treatment (dashed line). 
N: number of patients; O: number of observed events. NN: only nor­
mal metaphases; AN: normal and abnormal metaphases; AA:only 
abnormal metaphases, (b) Actuarial disease-free survival of nine pati­
ents with nonna! cytogenetic metaphases (NN) prior to treatment 
(solid line) and 16 patients with abnormal metaphases (AN-AA) prior 
to treatment (dashed line)
50% of the 10genetic abnormalities. The 2-year survival was 
patients with no cytogenetic abnormalities, while 21% of the 
patients with abnormal metaphases survived 2 years after 
registration (Figure 2a). This difference was statistically differ­
ent (P = 0.02). The DFS at 2 years was 8 vs 33%, respectively, 
for patients with or without cytogenetic abnormalities 
(P = 0.02) (Figure 2b). Two of the three patients still in CR at 
the time of analysis had no chromosomal abnormalities, but 
the marrow of the third patient showed multiple chromosomal 
abnormalities before start of treatment.
Table 3 Influence of cytogenetic abnormalities on CR rate
Cytogenetic data Number of patients CR (% ) P value
No data 5 2 (40)
Only normal (NN) 10 9 (90)
Other (AN + AA) 35 16 (46) 0.03
Discussion
Conventional, multidrug chemotherapy, used to induce com­
plete remission (CR) in de novo AML, has been demonstrated 
to be effective in MDS with CR rates varying from 15 to 
6 4 o/q 26-20,34 |n present/ prospective, multicenter study 27
out of 50 evaluable patients (54%) achieved CR. One 
additional patient entered CR after salvage chemotherapy 
resulting in an overall CR rate of 56%. The remission status 
was confirmed by cytogenetic analysis in the majority of pati­
ents with cytogenetic abnormalities prior to treatment. Cyto­
genetic analysis in remission was performed in nine of the 
16 remitters with cytogenetic abnormalities prior to treatment. 
Eight of nine patients showed only normal meta phases.
The high failure rate of remission-induction therapy can be 
explained partly by the long duration of hypoplasia after 
chemotherapy, but also by a high drug resistance of the leu­
kemic clone. A long duration of hypoplasia after remission- 
induction therapy has been reported by several groups*27,35,36 
This resulted in a toxic death rate ranging from 14 to 
21 % .27,35,36 The prolonged period of hypoplasia has not been 
shown to be consistent in all studies.20,37 In the current study, 
the toxic death rate during induction therapy was only 8%. 
The duration of hypoplasia was not recorded, but the average 
duration of hospitalization during and after the first remission- 
induction course lasted only 30 days which suggests a rela­
tively fast marrow recovery. Moreover, no fatalities occurred 
during prolonged hypoplasia.
Untreated cases of myelodysplastic syndromes appeared to 
have a higher incidence of the multidrug phenotype associ­
ated with the P-glycoprotein (PGP) compared to de novo 
AML,30'39 CR was achieved more frequently in PGP-negative 
cases after treatment with intensive anthracycline-Ara-C 
chemotherapy compared to PGP-positive cases.40 In the cur­
rent study, relative (five patients) or absolute resistance (14 
patients) was the major reason of failure of this relatively mild 
remission-induction therapy.
Some patients with MDS in CR after combination chemo­
therapy may achieve prolonged, disease-free survival,26,41 but 
overall median remission duration was short and usually less 
than 12 months.27,29 In the present study, only three out of 
the 28 remitters have remained in first CR, but four additional 
patients entered a second CR of substantial duration. The 
median survival duration of the complete remitters was 21 
months and 38% of these patients were still alive 2 years after 
registration. The overall survival at 2 years was 27% (Figure 
1).
Several prognostic characteristics may be identified in MDS 
and sAML. Patients with the morphological picture of RAEB27 
and RAEBt,41 seemed to respond favourably to intensive 
chemotherapy, approaching remission rates of those seen in 
de novo AML. Patients with secondary AML evolved from 
MDS responded less well to chemotherapy than did those 
with de novo leukemias and long-term remissions were 
rare.8,27,28 Certain subcategories of patients with sAML may 
show response rates similar to de novo AML.8,27,20 Patients 
with the morphologic picture of RAEB or RAEBt responded 
less well in this study compared to the patients who had pro­
gressed to AML. The DFS or sAML patients was significantly 
( P — 0.03) better in the current study despite a younger age 
in the MDS patient group and a shorter interval between diag­
nosis and treatment The explanation for this may be the rela­
tively high number of MDS patients with cytogenetic abnor­
malities: 26 out of 34 patients. The clinical outcome after 
intensive chemotherapy for therapy-related MDS and AML (t-
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MDS/t-AMl) is generally poor with only a low number of pati­
ents surviving beyond 1 year.26,41 In the present study, none 
of the eight therapy-related MDS or AML survived for more 
than 3 years after initiation of chemotherapy.
Some groups have reported data on patients initially diag­
nosed as having de novo AML and retrospectively rediag­
nosed as MDS.34,42 These patients probably represent a subca­
tegory of MDS with a short history plus clinical and/or 
cytogenetic features resembling de novo AML. Results of com­
bination chemotherapy in this category of patients may be bet­
ter than in the general population of patients with MDS. Bern­
stein43 observed no relevant differences of response rates and 
survival in patients retrospectively rediagnosed as RAEB, 
RAEBt or AML treated with frontline CALGB AML protocols. 
Similarly MDS patients treated within 3 months of diagnosis 
showed a better response to intensive chemotherapy.41 in this 
study all patients were to have clearcut MDS or AML after a 
well-defined preceding phase of MDS of at least 3 months 
duration. The cytogenetic data here support the myelodysplas­
tic nature of the patients in this study. Only one patient had 
chromosomal abnormalities associated with de novo AML. 
Moreover, 35 out of the 50 patients had clonal chromosomal 
abnormalities. The presence of cytogenetic abnormalities 
specific for MDS, such as abnormalities of chromosomes 5 or 
7 has a major negative impact on the prognosis after combi­
nation chemotherapy. Fenaux et a/41 observed a CR rate of 
57% in MDS patients with a normal karyotype contrasting 
with a CR rate of 31 %  in patients with rearrangements of chro­
mosomes 5 or 7. In this study patients with only normal meta­
phases in the bone marrow had a significantly better outcome 
compared to patients with chromosomal abnormalities. The 
numbers were too small to allow analysis of certain subgroups 
of patients.
ABMT has been performed in an occasional patient with 
MDS or sAML.44'45 ABMT was not recommended within the 
present study. Nevertheless; five patients were treated with 
ABMT. Four patients have relapsed and only one patient 
remains in CCR. No conclusions can be drawn from this lim­
ited number of patients.
Allogeneic BMT is considered to be the treatment of choice 
for young patients (age below 55 years) with MDS or sAML if 
an HLA-identical sibling donor is available,46“49 If allogeneic 
BMT for MDS is performed during a stage of excess of blasts 
(RAEB or RAEBt) or during overt transformation then a relapse 
risk of 50-80% may be expected.48,49 For that reason most 
European centers elected to treat these patients with allo-BMT 
after an attempt to induce CR with chemotherapy.50 In this 
study, five patients were allografted with marrow from an 
identical sibling, Four patients were transplanted after failure 
of remission-induction therapy. Two patients relapsed after 
BMT and two patients died due to transplant-related compli­
cations. One patient received the allograft in first CR, relapsed 
5 months after BMT, but achieved second CR 41 months after 
second BMT with signs of mild chronic graft-versus-host dis­
ease, The first graft consisted of bone marrow depleted of T 
lymphocytes by counterflow élutriation5"1 whilst the second 
graft was carried out using unmanipulated marrow.
The data of this study show that patients below the age of 
60 years with poor risk features may be considered for treat­
ment with combination chemotherapy. A complete remission 
rate of more than 50% may be expected. Failure to achieve 
CR was not due to persisting marrow aplasia or due to a high 
treatment-related fatality but due to persisting disease. Main­
taining remission after remission-induction chemotherapy is 
difficult. Patients not eligible for allogeneic BMT could be
treated with intensive, post-remission chemotherapy or auto­
logous BMT preferentially within the frame-work of prospec­
tive studies. The ongoing EORTC/EBMT study for this patient 
category evaluates the role of a more intensified remission- 
induction schedule followed by an intensive consolidation 
and either autologous stem cell transplantation or allogeneic 
bone marrow transplantation.
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